Ulteriori informazioni
Informationen zum Autor Professor Clive P. Page, BSc PhD OBE HonFBPhS is a Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of and on boards of several companies. He was awarded the Society of Biology President’s Medal in 2012 for an outstanding contribution to the life sciences over the previous year. He is a Fellow of the Royal Society of Biology and an Honorary Fellow and President Elect of the British Pharmacological Society. In 2017, Clive was awarded an OBE for Services to Pharmacology. Klappentext The consequences for diseases involving the immune system such as AIDS, and chronic inflammatory diseases such as bronchial asthma, rheumatoid athritis, and atherosclerosis, now account for a considerable economic burden to governments worldwide. In response there has been an enormous research effort investigating the basic mechanisms underlying such diseases, and a tremendous drive to identify novel therapeutic applications for their preventions and treatment. Though a plethora of immunological studies have been published in recent years, little has been written about the implications of such research for drug development. As a consequence, this area has not gained the prominence of other new fields such as molecular pharmacology or neuropharmacology, and a focal information source for many pharmacologists interested in diseases of the immune system remains unpublished. The Handbook of Immunopharmacology series provides such a source through the commissioning of a comprehensive collection of volumes on all aspects immunopharmacology. Editors have been sought after for each volume who are not only active in their respective areas of expertise, but who also have distinctly pharmacological bias to their research. The series follows three main themes, each represented by volumes on individual component topics. The first covers each of the major cell types and classes of inflammatory responses that can affect them ("Systems"). The third covers different classes of diseases as well as those under development ("Drugs"). Zusammenfassung Covers various aspects of immunopharmacology. This work covers each of the major cell types and classes of inflammatory responses. It covers different classes of diseases as well as the drugs under development. Inhaltsverzeichnis Contributors. Series Preface. Preface. Introduction. The Background to Autoimmunity, W.M. Williams, M.R. Ehrenstein, and D.A. Isenberg . Immunological Tolerance and its Implications for Autoimmunity, N.A. Mitchison . Peptide Blockade and Antigen-specific Modulation of Autoimmune Disease, D.C. Wraith . Monoclonal Antibody Therapy of Experimental Arthritis - Comparison with Cyclosparin A for Elucidating Cellular and Molecular Disease Mechanisms, M.E.J. Billingham . Anti-CD4 and Other Antibodies to Cell Surface Antigens for Therapy, F. Emmrich, H. Schulze-Koops, and G. Burmester . Are Imbalances in Cytokine Function of Importance in the Pathogenesis of Rheumatoid Arthritis?, M. Feldmann, F.M. Brennan, E.R. Abney, A. Hales, Y. Chernajovsky, P. Katsikis, A. Corcoran, C. Haworth, A. Cope, D. Gibbons, C.Q. Chu, M. Field, B. Deleuran, R.O. Williams, and R.N. Maini . Naturally Occuring Inhibitors of Cytokines, W.P. Arend and J.-M. Dayer . Soluble Immunopeptides in Inflammatory Arthritis, J.A. Symons and G.W. Duff . Inflammatory Reactions in Arthritis, H.-G. Fassbender . Connective Tissue Destruction in Rheumatoid A...
